Member since: 2019
Organization: Bristol Myers Squibb
2022 will be a great year for biomarker discovery.
Application Area: Biomarker discovery
"This is a relatively new capability available to the consumer. From a very low volume of sample, we can analyze the relative prevalence of 90 proteins. The assay is sensitive and accurate."
Our Oncology II panel provides a high-throughput, multiplex immunoassay enabling analysis of 92 cancer-related protein biomarkers across 96 samples simultaneously. This high level of multiplexing is achieved without any compromise on data quality, thanks to our proprietary Proximity Extension Assay (PEA) technology.
Together with our ONCOLOGY III panel, this represents the most extensive solution available for proteins associated with cancer and oncology-related biological processes, enabling investigation of protein signatures with high efficiency and robustness and accelerates the speed of finding new and relevant human protein biomarkers related to oncology. The panel is compiled to detect a selection of already established as well as exploratory biomarkers within the oncology research field. The content of the panel has been designed in close collaboration with experts within the field, and it is well suited to discerning protein profiles in clinically relevant samples.
The panel is available via fee-for-service analysis, or as a reagent kit (requires a Fludigm® Biomark qPCR instrument to run)